The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.
Pharmacokinetics of valproic acid in volunteers after a single dose study
โ Scribed by Meir Bialer; Ziad Hussein; Itamar Raz; Oded Abramsky; Yuval Herishanu; Freddy Pachys
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 432 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
The pharmacokinetics of valproic acid (VPA) was investigated in six healthy volunteers. This was done by monitoring total and free (unbound) valproic acid levels in the serum, and the amount of one of its metabolites, VPA glucuronide, in the urine as a function of time, after a single dose administration of the parent drug. VPA half-life calculated from the urine data of the metabolite was shorter than the half-life calculated from the blood data. About 15 to 20 per cent of the administered oral dose of VPA was excreted in the urine as VPA glucuronide. The average free fraction of VPA obtained in this study, by using the EMIT technique, ranged from 1.5 to 11.5 per cent with a mean value of 4.9 per cent.
๐ SIMILAR VOLUMES
The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of
The aim of this study was to assess the pharmacokinetic profile of pancopride after repeated oral dose administration of 20mg pancopride in tablet form once a day for 5 d in 12 healthy male volunteers. Plasma levels were measured by HPLC using a solid phase extraction method and automated injection.
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg
The dose-dependent pharmacokinetics of caeic acid (CA) were studied in rabbits. Three dierent doses (5, 10, and 25 mg kg 71 ) were administered intravenously to six rabbits each. The concentrationยฑtime proยฎles for CA could be ยฎtted by a twocompartment model for each dose. The results showed that tot